Recent Advances in the Treatment of Multiple Myeloma: Highlights from the ASH 2021 Meeting
EP. 1: Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM: Focus on GRIFFIN and MASTER Trials
ByRafael Fonseca, MD,Caitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.
EP. 2: Choosing Between Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM
ByRafael Fonseca, MD,Caitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD A discussion on choosing between triplet or quadruplet induction therapy for transplant-eligible newly diagnosed multiple myeloma.
EP. 3: Treatment Duration and Response to Induction Therapy in Transplant-Eligible NDMM
ByRafael Fonseca, MD,Caitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.
EP. 4: First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial
ByCaitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD,Rafael Fonseca, MD A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.
EP. 5: Outcomes with Daratumumab in Frontline Versus Subsequent Lines of Therapy in Transplant-Ineligible MM
ByRafael Fonseca, MD,Caitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.
EP. 6: Novel BCMA-Targeting Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
ByRafael Fonseca, MD,Krina K. Patel, MD,Caitlin Costello, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.
EP. 7: BCMA-Targeting Bispecific Agents for Relapsed/Refractory Multiple Myeloma Treatment
ByRafael Fonseca, MD,Caitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.
EP. 8: CAR-T Therapies in Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 and KarMMA Studies
ByRafael Fonseca, MD,Caitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.
EP. 9: Novel Agents Under Investigation for Multiple Myeloma
ByRafael Fonseca, MD,Caitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.
EP. 10: Unmet Needs and Future Perspectives in Multiple Myeloma Treatment
ByRafael Fonseca, MD,Caitlin Costello, MD,Krina K. Patel, MD,Jeffrey V. Matous, MD,Robert Z. Orlowski, MD, PhD A look at the unmet needs and future directions of multiple myeloma treatment.
A panel of experts provides a discussion on treatments for newly diagnosed transplant-eligible and transplant-ineligible relapsed multiple myeloma, and how recent clinical trial data presented at ASH 2021 can be applied to clinical practice.
